FDA Sets Peptide Impurity Thresholds as Low as 0.10%, Oath Research Analysis Finds
FDA guidance for synthetic peptide drugs requires identification of impurities above 0.10% and caps new impurities at 0.5% — U.S. FDA, 2021 GILBERT, Ariz., June 30, 2026 /PRNewswire/ -- Oath Research, a Gilbert, Arizona–based research peptide supplier, today released an analysis of the...
FDA guidance for synthetic peptide drugs requires identification of impurities above 0.10% and caps new impurities at 0.5% — U.S. FDA, 2021 GILBERT, Ariz., June 30, 2026 /PRNewswire/ -- Oath Research, a Gilbert, Arizona–based research peptide supplier, today released an analysis of the...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.